Cystic Fibrosis: Pathophysiology and Clinical Overview

Cystic fibrosis (CF) is a chronic, inherited disorder that affects multiple organ systems, most notably the lungs and gastrointestinal tract. It is characterized by abnormal ion transport across epithelial cells, leading to thick, dehydrated secretions that impair normal organ function.

Although advances in treatment have improved life expectancy, CF remains a progressive condition that requires lifelong management.

Understanding its genetic basis, pathophysiology, and clinical manifestations is essential for healthcare professionals, especially those involved in respiratory care and long-term disease management.

What Is Cystic Fibrosis?

Cystic fibrosis is a chronic, inherited disorder that affects the lungs, digestive system, and other organs. It is caused by mutations in the CFTR gene, which disrupt normal chloride and water transport across epithelial cells. This leads to thick, sticky mucus that obstructs the airways and ducts.

In the lungs, mucus buildup impairs clearance, promotes infection, and causes progressive lung damage. In the digestive system, it blocks pancreatic enzymes, leading to malabsorption and poor nutrition.

Common symptoms include a persistent cough, frequent respiratory infections, and difficulty gaining weight. Although treatments have improved outcomes, cystic fibrosis remains a lifelong condition that requires ongoing medical care.

Epidemiology and Incidence

Cystic fibrosis is one of the most common autosomal recessive genetic disorders in the United States. It occurs in approximately 1 in 3,500 live births, with around 1,000 new cases diagnosed each year. The disease affects about 30,000 individuals in the United States and an estimated 70,000 people worldwide.

The prevalence of CF varies among different populations. It is most common in individuals of Northern European descent, with an incidence of approximately 1 in 3,200 births. In comparison, it occurs less frequently in Hispanic populations, African Americans, and Asian Americans. These variations reflect differences in the distribution of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Note: Because CF is inherited in an autosomal recessive pattern, both parents must carry a defective gene for a child to be affected. Carriers typically do not show symptoms but can pass the mutation to their offspring.

Genetic Basis and Pathophysiology

Cystic fibrosis is caused by mutations in the CFTR gene, which encodes a protein responsible for regulating chloride transport across epithelial cell membranes. This protein plays a key role in maintaining the balance of salt and water on cell surfaces.

In individuals with CF, the CFTR protein is either absent or dysfunctional. This leads to impaired chloride secretion and increased sodium absorption. As a result, water movement across the epithelial surface is reduced, causing dehydration of the airway lining.

The consequences of this defect are significant:

• Mucus becomes thick and sticky
• Airway surfaces become dry
• Mucociliary clearance is impaired

Under normal conditions, mucus traps pathogens and particles while cilia move this material out of the airways. In CF, this clearance mechanism fails, allowing mucus to accumulate and obstruct the airways.

This environment promotes:

• Chronic bacterial colonization
• Persistent inflammation
• Progressive tissue damage

Note: Over time, repeated cycles of infection and inflammation lead to structural changes in the lungs, including airway remodeling and destruction of lung tissue.

Pulmonary Manifestations

The lungs are the most critically affected organ system in cystic fibrosis. Pulmonary disease is the leading cause of morbidity and mortality in these patients.

Early in the disease, patients may develop a chronic cough that produces thick sputum. As mucus accumulates, it obstructs airflow and creates an ideal environment for bacterial growth. This leads to recurrent respiratory infections, which become more frequent and severe over time.

Common pulmonary features include:

• Chronic productive cough
• Wheezing
• Dyspnea
• Reduced exercise tolerance
• Frequent pulmonary exacerbations

As the disease progresses, lung function steadily declines. Repeated infections and inflammation damage the airway walls, resulting in bronchiectasis, a condition characterized by permanent dilation of the bronchi.

Certain pathogens are strongly associated with CF. These include:

• Pseudomonas aeruginosa, particularly in older patients
• Staphylococcus aureus
• Burkholderia cepacia complex

Colonization with these organisms contributes to chronic infection and accelerates lung damage. Pseudomonas aeruginosa is especially concerning because it is difficult to eradicate and often becomes resistant to multiple antibiotics.

Advanced pulmonary complications may include:

• Hemoptysis
• Pneumothorax
• Respiratory failure

Note: These complications reflect the progressive nature of the disease and the cumulative impact of chronic infection and airway obstruction.

Gastrointestinal and Nutritional Effects

Cystic fibrosis also has a significant impact on the gastrointestinal system, particularly the pancreas. Thick secretions obstruct pancreatic ducts, preventing digestive enzymes from reaching the small intestine.

This results in pancreatic insufficiency, which leads to:

• Impaired digestion of fats and proteins
• Malabsorption of nutrients
• Steatorrhea
• Poor weight gain

Patients with CF often struggle to maintain adequate nutrition, especially during childhood. Failure to thrive is a common early sign of the disease.

In addition to macronutrient malabsorption, deficiencies in fat-soluble vitamins are common. These include vitamins A, D, E, and K, which require proper fat digestion for absorption.

Nutritional management is a critical component of CF care and typically includes:

• High-calorie, high-fat diets
• Pancreatic enzyme replacement therapy
• Vitamin supplementation

Maintaining good nutritional status is strongly associated with better lung function and improved long-term outcomes.

Other gastrointestinal complications may include:

• Meconium ileus in newborns
• Distal intestinal obstruction syndrome
• Liver disease due to bile duct obstruction

Note: These issues highlight the systemic nature of CF and the need for comprehensive management.

Clinical Features

Patients with cystic fibrosis often present with a combination of respiratory and systemic symptoms. The severity and progression of symptoms can vary depending on the specific CFTR mutation and the effectiveness of treatment.

Common clinical features include:

• Persistent cough with thick mucus
• Recurrent respiratory infections
• Wheezing and shortness of breath
• Poor growth and weight gain
• Fatigue and reduced exercise tolerance

One distinctive feature of CF is salty-tasting skin. This occurs because of abnormal electrolyte transport in sweat glands, leading to increased chloride and sodium levels in sweat.

As the disease progresses, physical signs may become more apparent. Digital clubbing is a common finding in advanced cases and reflects chronic hypoxemia. The variability in clinical presentation means that some patients are diagnosed early in life, while others may not be identified until later, especially in milder cases.

Diagnosis

The diagnosis of cystic fibrosis is based on a combination of clinical findings and laboratory testing. The gold standard diagnostic test is the sweat chloride test. This test measures the concentration of chloride in sweat, which is elevated in individuals with CF due to defective ion transport.

Key diagnostic criteria include:

• Elevated sweat chloride levels
• Presence of characteristic clinical features
• Identification of CFTR gene mutations

Newborn screening programs have significantly improved early detection of CF. These programs allow for diagnosis before symptoms become severe, enabling earlier intervention and better outcomes.

Genetic testing is also used to confirm the diagnosis and identify specific mutations. This information can guide treatment decisions, particularly with the use of CFTR modulator therapies.

Respiratory Care and Airway Clearance

Effective respiratory care is central to managing cystic fibrosis. One of the primary goals is to remove thick secretions from the airways to improve ventilation and reduce infection risk.

Airway clearance techniques are used daily and are tailored to the individual patient. These methods include:

• Chest physiotherapy
• Postural drainage
• Positive expiratory pressure therapy
• Oscillatory devices
• Mechanical airway clearance systems

These therapies help mobilize mucus, making it easier to expectorate. Consistent use is essential for maintaining airway patency and preventing complications.

Positive expiratory pressure therapy is particularly useful because it helps keep small airways open and promotes the movement of secretions toward larger airways, where they can be cleared more effectively.

Note: Respiratory therapists play a key role in teaching and optimizing these techniques, ensuring that patients and caregivers can perform them correctly at home.

Aerosol and Pharmacologic Therapy

In addition to airway clearance, aerosolized medications are widely used to improve respiratory function in CF patients.

Common therapies include:

Bronchodilators

These medications help relax airway smooth muscle and improve airflow. They are often administered before airway clearance to enhance effectiveness.

Mucolytics

Dornase alfa is commonly used to reduce mucus viscosity by breaking down DNA in airway secretions. This improves mucus clearance and lung function.

Hypertonic saline

This therapy helps hydrate airway surfaces, making mucus less thick and easier to remove.

Antibiotics

Inhaled antibiotics such as tobramycin are used to suppress chronic bacterial infections, particularly those caused by Pseudomonas aeruginosa. Systemic antibiotics may be required during acute exacerbations.

Note: These pharmacologic treatments are often used in combination and must be adjusted based on the patient’s clinical status and response to therapy.

CFTR Modulator Therapy

A major advancement in the treatment of cystic fibrosis is the development of CFTR modulator medications. Unlike traditional therapies that focus on managing symptoms, these drugs target the underlying defect in the CFTR protein.

CFTR modulators work by improving the function of the defective protein. Depending on the specific mutation, these medications may:

• Enhance the movement of CFTR proteins to the cell surface
• Improve the opening of chloride channels
• Increase overall ion transport across epithelial cells

Examples include ivacaftor, lumacaftor, and combination therapies that are tailored to specific genetic mutations.

These treatments have led to measurable improvements in lung function, reduced pulmonary exacerbations, and enhanced quality of life in eligible patients. However, not all individuals with CF benefit from these therapies, as effectiveness depends on the type of CFTR mutation present.

Note: Because of this, genetic testing plays a key role in determining whether a patient is a candidate for CFTR modulator therapy.

Infection Control

Patients with cystic fibrosis are at high risk for chronic and recurrent infections. Effective infection control measures are essential in both hospital and home settings.

Cross-infection between patients is a significant concern, especially with organisms such as Pseudomonas aeruginosa and Burkholderia cepacia complex. These pathogens can be transmitted through respiratory droplets or contaminated equipment.

Recommended infection control practices include:

• Using dedicated respiratory equipment for each patient
• Thorough cleaning and disinfection of nebulizers and airway clearance devices
• Adherence to strict hand hygiene
• Avoiding close contact between individuals with CF

Note: In healthcare settings, patients may be placed under isolation precautions to minimize the risk of transmission. Education on infection prevention is critical and should be reinforced regularly by healthcare providers.

Role of the Respiratory Therapist

Respiratory therapists play an essential role in the management of cystic fibrosis. Their responsibilities extend beyond performing procedures to include patient education, monitoring, and long-term care planning.

Key responsibilities include:

• Administering airway clearance therapies
• Delivering aerosolized medications
• Monitoring respiratory status and lung function
• Assisting in the management of ventilatory support when needed

Respiratory therapists also provide education to patients and families, ensuring they understand how to perform therapies correctly at home. This includes instruction on proper technique, frequency of treatments, and equipment maintenance.

Note: Ongoing assessment is important, as treatment plans must be adjusted based on changes in the patient’s condition, including increases in secretion production or declines in lung function.

Complications

Cystic fibrosis is associated with a wide range of complications that affect multiple organ systems. These complications contribute to disease progression and often require specialized management.

Pulmonary Complications

• Chronic respiratory failure
• Bronchiectasis
• Hemoptysis
• Pneumothorax

Note: These conditions result from long-term airway obstruction, infection, and inflammation.

Gastrointestinal and Metabolic Complications

• Malnutrition
• Fat-soluble vitamin deficiencies
• Liver disease due to bile duct obstruction

In addition, infertility is a common issue, particularly in males, due to congenital absence or dysfunction of the vas deferens.

As patients live longer, other complications may emerge, including diabetes related to pancreatic dysfunction and decreased bone density. The presence and severity of complications vary among individuals and are influenced by factors such as genetic mutations, adherence to therapy, and overall health status.

Monitoring and Long-Term Care

Cystic fibrosis requires continuous monitoring and long-term management. Regular follow-up visits are essential to assess disease progression and adjust treatment strategies.

Monitoring typically includes:

• Pulmonary function testing to evaluate lung capacity and airflow
• Assessment of respiratory symptoms and frequency of exacerbations
• Evaluation of nutritional status and growth
• Laboratory testing to monitor vitamin levels and organ function

Imaging studies, such as chest radiographs or computed tomography scans, may be used to assess structural lung changes, including bronchiectasis. Early identification of changes in lung function or infection status allows for timely intervention, which can help slow disease progression.

Multidisciplinary care teams are often involved in managing CF. These teams may include physicians, respiratory therapists, dietitians, nurses, and social workers, all working together to address the complex needs of the patient.

Prognosis

The prognosis for individuals with cystic fibrosis has improved significantly over the past several decades. Advances in early diagnosis, airway clearance techniques, antibiotic therapy, and CFTR modulators have contributed to increased survival rates.

Many patients now live into adulthood, with some reaching middle age or beyond. However, cystic fibrosis remains a progressive disease, and lung function typically declines over time.

Prognosis is influenced by several factors, including:

• Baseline lung function
• Nutritional status
• Frequency and severity of infections
• Access to specialized care

Note: Chronic respiratory failure remains the most common cause of death in patients with CF. Early intervention, consistent adherence to treatment, and comprehensive care can improve both quality of life and longevity.

Cystic Fibrosis Practice Questions

1. What is cystic fibrosis?
Cystic fibrosis is a genetic disorder that causes thick, sticky mucus to accumulate in the lungs and other organs due to defective chloride transport.

2. What type of genetic inheritance pattern does cystic fibrosis follow?
It follows an autosomal recessive inheritance pattern.

3. What protein is defective in cystic fibrosis?
The cystic fibrosis transmembrane conductance regulator (CFTR) protein.

4. What is the primary function of the CFTR protein?
It regulates chloride transport across epithelial cell membranes.

5. How does CFTR dysfunction affect mucus in the airways?
It leads to dehydrated, thick, and viscous mucus.

6. Why is mucociliary clearance impaired in cystic fibrosis?
Because thick mucus and reduced airway surface liquid prevent cilia from effectively moving secretions.

7. What is the most critically affected organ system in cystic fibrosis?
The respiratory system.

8. What is the leading cause of death in cystic fibrosis patients?
Respiratory failure

9. What is bronchiectasis, and how is it related to cystic fibrosis?
Bronchiectasis is permanent airway dilation caused by chronic infection and inflammation in CF.

10. Which pathogen is most commonly associated with older cystic fibrosis patients?
Pseudomonas aeruginosa

11. Name two other pathogens commonly seen in cystic fibrosis patients.
Staphylococcus aureus and Burkholderia cepacia complex.

12. What causes pancreatic insufficiency in cystic fibrosis?
Obstruction of pancreatic ducts by thick secretions.

13. What is a common nutritional consequence of cystic fibrosis?
Malabsorption leading to poor weight gain.

14. Which types of vitamins are commonly deficient in cystic fibrosis patients?
Fat-soluble vitamins A, D, E, and K.

15. What is the gold standard test for diagnosing cystic fibrosis?
The sweat chloride test.

16. What happens to sodium absorption in cystic fibrosis?
Sodium absorption increases due to CFTR dysfunction.

17. How does decreased water movement affect the airway surface in CF?
It causes dehydration of the airway surface, leading to thick mucus.

18. What is a common respiratory symptom seen in cystic fibrosis patients?
A chronic productive cough with thick sputum.

19. Why are cystic fibrosis patients prone to recurrent infections?
Because thick mucus traps bacteria and impairs clearance.

20. What distinctive physical finding is often associated with cystic fibrosis?
Salty-tasting skin due to elevated chloride in sweat.

21. What early gastrointestinal condition may be seen in newborns with CF?
Meconium ileus

22. What is the purpose of pancreatic enzyme replacement therapy in CF?
To aid digestion and improve nutrient absorption.

23. What is the role of hypertonic saline in CF treatment?
It helps hydrate airway secretions and improve mucus clearance.

24. What is the mechanism of action of dornase alfa (Pulmozyme)?
It breaks down DNA in mucus to reduce viscosity.

25. Why is acetylcysteine generally avoided in CF patients?
Because it is less effective and can cause bronchospasm.

26. What is the purpose of airway clearance therapy in CF?
To mobilize and remove thick secretions from the lungs.

27. What does positive expiratory pressure (PEP) therapy help accomplish?
It helps keep small airways open and moves secretions toward larger airways.

28. What is one serious pulmonary complication of cystic fibrosis?
Pneumothorax

29. Why is infection control especially important in CF patients?
To prevent cross-infection with harmful bacteria.

30. What is the primary goal of CFTR modulator therapy?
To improve the function of the defective CFTR protein.

31. What is cystic fibrosis characterized by?
A genetic disorder causing thick, dehydrated secretions that lead to chronic lung infection and pancreatic malabsorption due to CFTR dysfunction.

32. What is the underlying defect in cystic fibrosis?
A mutation in the CFTR protein that impairs chloride transport across epithelial cell membranes.

33. What happens in the lungs of patients with cystic fibrosis?
Thick mucus accumulates, leading to airway obstruction and chronic respiratory infections.

34. What happens in the pancreas in cystic fibrosis?
Thick secretions obstruct pancreatic ducts, preventing digestive enzymes from reaching the intestines.

35. Which body system is primarily affected in cystic fibrosis?
The exocrine system.

36. What causes thick, sticky secretions in cystic fibrosis?
Defective chloride transport combined with increased sodium absorption leads to dehydrated mucus.

37. Which population has the highest prevalence of cystic fibrosis?
Individuals of Northern European (Caucasian) descent.

38. What are common chest X-ray findings in cystic fibrosis?
Hyperinflation, bronchial wall thickening, and areas of atelectasis.

39. What is the gold standard diagnostic test for cystic fibrosis?
The sweat chloride test.

40. Which two pathogens are commonly associated with cystic fibrosis infections?
Staphylococcus aureus and Pseudomonas aeruginosa.

41. What are common pulmonary complications of cystic fibrosis?
Bronchiectasis, atelectasis, pneumothorax, hemoptysis, and respiratory failure.

42. What are common extrapulmonary complications of cystic fibrosis?
Malnutrition, cystic fibrosis-related diabetes, GERD, pancreatitis, infertility, and liver disease.

43. How many positive sweat chloride tests are typically required to confirm cystic fibrosis?
Two positive results on separate occasions.

44. What are common signs and symptoms of cystic fibrosis?
Chronic productive cough, salty sweat, malnutrition, steatorrhea, and recurrent lung infections.

45. What are common gastrointestinal symptoms in cystic fibrosis?
Fatty stools, abdominal distention, and poor weight gain.

46. What therapies are commonly used to manage cystic fibrosis?
Airway clearance therapy, dornase alfa, bronchodilators, hypertonic saline, and antibiotics.

47. What airway clearance techniques are used in cystic fibrosis?
Chest physiotherapy, postural drainage, PEP therapy, and high-frequency chest wall oscillation.

48. What additional treatments may be used in cystic fibrosis management?
Pancreatic enzyme replacement, vitamin supplementation, oxygen therapy, and CFTR modulators.

49. What is the current prognosis for cystic fibrosis?
There is no cure, but advances in treatment have significantly improved life expectancy into adulthood.

50. What types of deficiencies are common in cystic fibrosis?
Fat-soluble vitamin deficiencies (A, D, E, and K).

51. What is a typical ABG finding in advanced cystic fibrosis?
Chronic respiratory acidosis with metabolic compensation.

52. What type of lung disease is cystic fibrosis classified as?
An inherited obstructive lung disease.

53. Where is the CFTR gene located?
Chromosome 7

54. What pathological lung changes are seen in cystic fibrosis?
Thick mucus, airway obstruction, hyperinflation, and bronchiectasis.

55. What is a common physical presentation of cystic fibrosis patients?
Malnutrition with chronic respiratory symptoms and excessive secretions.

56. What gastrointestinal condition is commonly seen in newborns with cystic fibrosis?
Meconium ileus

57. What reproductive complication is common in males with cystic fibrosis?
Infertility due to absence of the vas deferens.

58. If both parents are carriers of the CFTR gene, what is the chance their child will be a carrier?
50 percent

59. What physical finding is commonly seen in the fingers of cystic fibrosis patients?
Digital clubbing

60. What causes digital clubbing in cystic fibrosis?
Chronic hypoxemia leading to changes in soft tissue and nail beds.

61. What is the current median predicted survival for people with cystic fibrosis?
It is now over 50 years in many developed countries due to advances in treatment.

62. What diagnostic finding confirms cystic fibrosis on laboratory testing?
An elevated sweat chloride level on two separate tests.

63. What are the core components of cystic fibrosis management?
Pancreatic enzyme replacement, airway clearance therapy, antibiotics, and nutritional support.

64. Why can cystic fibrosis patients appear malnourished despite a high-calorie diet?
Because pancreatic insufficiency leads to poor absorption of nutrients.

65. What antibiotic is commonly used to treat Pseudomonas aeruginosa in cystic fibrosis?
Inhaled tobramycin (TOBI)

66. Which surgical option may be considered for advanced cystic fibrosis lung disease?
Lung transplantation

67. What percussion note is commonly heard in patients with cystic fibrosis?
Hyperresonance due to air trapping and hyperinflation.

68. What are typical breath sounds in cystic fibrosis patients?
Crackles due to mucus and airway secretions.

69. What is a common upper airway manifestation of cystic fibrosis?
Chronic sinusitis

70. Which vitamins must be supplemented in cystic fibrosis patients?
Fat-soluble vitamins A, D, E, and K.

71. What device can be used as an alternative to manual chest percussion?
High-frequency chest wall oscillation (vest therapy).

72. What medications are commonly used in cystic fibrosis airway management?
Bronchodilators, dornase alfa, hypertonic saline, and inhaled antibiotics.

73. What factors contribute to bone disease in cystic fibrosis?
Vitamin D deficiency, malnutrition, delayed growth, inactivity, and corticosteroid use.

74. What protein is defective in cystic fibrosis?
The CFTR (cystic fibrosis transmembrane conductance regulator) protein.

75. What factors may contribute to poor appetite in children with cystic fibrosis?
Fatigue, chronic illness, psychological stress, and increased energy demands.

76. How are pancreatic enzyme supplements administered to infants and young children?
They are mixed with soft acidic foods such as applesauce.

77. If both parents are carriers of cystic fibrosis, what is the probability their child will have the disease?
25 percent

78. What proportion of cystic fibrosis patients have pancreatic insufficiency?
Approximately 85 percent.

79. What gastrointestinal conditions are associated with cystic fibrosis?
Meconium ileus and distal intestinal obstruction syndrome.

80. What pulmonary changes occur in cystic fibrosis?
Chronic infection, inflammation, mucus plugging, and bronchiectasis.

81. What is the most common CFTR gene mutation?
Deletion of phenylalanine at position 508 (ΔF508).

82. What happens in the sweat glands of cystic fibrosis patients?
Reduced chloride reabsorption leads to increased sodium and chloride in sweat.

83. What is the “low-volume” model in cystic fibrosis?
Reduced chloride secretion leads to decreased water in mucus, resulting in thick, dehydrated secretions.

84. Which two major organs are most affected by thick mucus in cystic fibrosis?
The lungs and pancreas.

85. What is the primary cause of airway obstruction in cystic fibrosis?
Accumulation of thick, dehydrated mucus in the airways.

86. What role do neutrophils play in cystic fibrosis lung disease?
They release enzymes and DNA that increase mucus viscosity and inflammation.

87. Why is dornase alfa effective in cystic fibrosis?
It breaks down extracellular DNA in mucus, reducing its thickness.

88. What is the purpose of hypertonic saline inhalation in cystic fibrosis?
To draw water into the airway surface and improve mucus clearance.

89. What type of infection pattern is common in cystic fibrosis lungs?
Chronic and recurrent bacterial infections.

90. What is the significance of biofilm formation in cystic fibrosis?
It protects bacteria from antibiotics and the immune system.

91. What is a common complication of advanced cystic fibrosis lung disease?
Respiratory failure

92. Why are bronchodilators used before airway clearance therapy?
To open the airways and improve secretion mobilization.

93. What is cystic fibrosis-related diabetes (CFRD)?
A form of diabetes caused by pancreatic damage and insulin deficiency.

94. What is the effect of chronic inflammation in cystic fibrosis lungs?
Progressive airway damage and decline in lung function.

95. What is forced expiratory volume in one second (FEV1) used for in cystic fibrosis?
To monitor lung function and disease progression.

96. What type of diet is recommended for cystic fibrosis patients?
A high-calorie, high-protein diet.

97. Why is salt supplementation often needed in cystic fibrosis?
Because excessive sodium is lost in sweat.

98. What is one benefit of regular exercise in cystic fibrosis patients?
It helps improve mucus clearance and overall lung function.

99. What is a common sign of worsening lung disease in cystic fibrosis?
Increased frequency of pulmonary exacerbations.

100. What is the primary goal of long-term management in cystic fibrosis?
To maintain lung function, prevent infections, and improve quality of life.

Final Thoughts

Cystic fibrosis is a complex, multisystem genetic disorder that requires a thorough understanding of its underlying mechanisms and clinical implications. The disease affects both the respiratory and gastrointestinal systems, leading to chronic complications that demand lifelong management.

Advances in therapy, particularly those targeting the CFTR protein, have improved outcomes, but challenges remain. Effective care depends on consistent airway clearance, infection control, and nutritional support.

Healthcare professionals, especially respiratory therapists, play a vital role in optimizing treatment and supporting patients throughout the course of the disease.